RODRIGUEZ RAUL R 4
4 · RIGEL PHARMACEUTICALS INC · Filed Feb 19, 2026
Research Summary
AI-generated summary of this filing
Rigel (RIGL) CEO Raul Rodriguez Receives Award
What Happened Raul R. Rodriguez, CEO, President and Director of Rigel Pharmaceuticals (RIGL), was granted 53,915 restricted stock units (RSUs) on February 17, 2026. The award is reported at $0.00 per share (total reported value $0) because these are compensation RSUs that convert to shares only upon vesting. This is an equity award (transaction code A), not an open-market purchase or sale.
Key Details
- Transaction date: 2026-02-17; Form 4 filed: 2026-02-19 (appears timely under the 2-business-day filing rule).
- Grant amount and price: 53,915 RSUs at $0.00 reported.
- Shares owned after transaction: Not specified in this Form 4.
- Footnote: The RSUs vest quarterly over three years; the first quarterly vesting date is March 31, 2026.
- No 10b5-1 plan, tax-withholding sale, or immediate sale reported in this filing.
Context RSUs are a form of compensation that convert to actual shares only as they vest; they do not represent an immediate cash purchase or sale. Such awards are common for executive pay and do not by themselves indicate a buy/sell signal — they increase potential future ownership if and when they vest.
Insider Transaction Report
- Award
Common Stock
[F1]2026-02-17+53,915→ 282,017 total
Footnotes (1)
- [F1]The shares of common stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall vest quarterly over three (3) years, with the first quarterly vest occurring on March 31, 2026.